NCT05770180View on ClinicalTrials.gov

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

July 30, 2023

Study Completion Date

April 9, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant COVID-19 variant vaccine (Sf9 cell)

WSK-V102

BIOLOGICAL

Recombinant COVID-19 vaccine (CHO cell)

control 1

BIOLOGICAL

Recombinant COVID-19 vaccine (Sf9 cell)

control 2

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Disease Prevention and Control, Nanjing

All Listed Sponsors
lead

WestVac Biopharma Co., Ltd.

INDUSTRY